Fast Track Designation reduces regulatory uncertainty and increases confidence in the drug’s development path. The sample size increase suggests the trial is adapting to maximize success probability, not signaling failure. With no safety issues and maintained enrollment timeline, this supports continued investment ahead of 2027 topline data readout.
Price Chart
Executive Summary
Aligos Therapeutics announced FDA Fast Track Designation for pevifoscorvir sodium in chronic HBV infection and an interim analysis outcome from its Phase 2 B-SUPREME study, where the DSMB recommended increasing the HBeAg- cohort sample size to optimize statistical power and confirmed futility criteria were not met. The drug remains well-tolerated, with topline data expected in 2027.
Key Facts
- FDA granted Fast Track Designation to pevifoscorvir sodium for chronic HBV infection, supporting potential for expedited development and review.
- DSMB recommended increasing HBeAg- cohort sample size from 74 to 100 participants after interim analysis of 34 patients at Week 12.
- Futility criteria were not met, indicating continued viability of the trial's primary endpoint.
- Study drugs showed no safety concerns across 174 enrolled participants, with no viral breakthrough observed.
- Topline data remains on track for 2027; enrollment completion expected in second half of 2026.
Financial Impact
Non-dilutive catalyst with significant value inflection potential; Fast Track status improves regulatory predictability and may accelerate path to approval.
Risk Factors
- Clinical trial delays beyond 2027 could erode investor confidence.
- Future data readouts may not confirm antiviral efficacy despite favorable safety profile.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3273893 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 6, 2026 11w ago | 8-K | $5.51 $6.77 | ▲ +22.87% | ▲ +21.65% | $4.70 (−14.70%) |
Jun 26, 2026 17w ago | 8-K | $5.43 $5.85 | ▲ +7.73% | ▲ +6.35% | $4.70 (−13.44%) |
May 27, 2026 21w ago | Press Release | $5.60 $5.14 | ▼ −8.21% | ▼ −8.68% | $4.70 (−16.07%) |
Apr 16, 2026 27w ago | Press Release | $7.66 $6.13 | ▼ −19.97% | ▼ −20.96% | $4.70 (−38.64%) |
Apr 14, 2026 27w ago | Press Release | $7.42 $6.51 | ▼ −12.26% | ▼ −13.90% | $4.70 (−36.66%) |
Mar 5, 2026 33w ago | 8-K | $6.66 $7.41 | ▲ +11.26% | ▲ +13.50% | $4.70 (−29.43%) |
Mar 5, 2026 33w ago | Press Release | $6.66 $7.41 | ▲ +11.26% | ▲ +13.50% | $4.70 (−29.43%) |
Feb 28, 2026 34w ago | Institutional Cluster | $6.97 $7.03 | ▲ +0.86% | ▲ +2.07% | $4.70 (−32.52%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers